Literature DB >> 31540849

Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Geoffrey L Rogers1, Hsu-Yu Chen1, Heidy Morales1, Paula M Cannon2.   

Abstract

Adeno-associated virus (AAV) vectors are frequently used as donor templates for genome editing by homologous recombination. Although modification rates are typically under 1%, they are greatly enhanced by targeted double-stranded DNA breaks (DSBs). A recent report described clade F AAVs mediating high-efficiency homologous recombination-based editing in the absence of DSBs. The clade F vectors included AAV9 and a series isolated from human hematopoietic stem and progenitor cells (HSPCs). We evaluated these vectors by packaging homology donors into AAV9 and an AAVHSC capsid and examining their ability to insert GFP at the CCR5 and AAVS1 loci in human HSPCs and cell lines. As a control, we used AAV6, which effectively edits HSPCs but only when combined with a targeted DSB. Each AAV vector promoted GFP insertion in the presence of matched CCR5 or AAVS1 zinc-finger nucleases (ZFNs), but none supported detectable editing in the absence of the nucleases. Rates of editing with ZFNs correlated with transduction efficiencies for each vector, implying no differences in the ability of donor sequences delivered by the different vectors to direct genome editing. Our results, therefore, do not support that clade F AAVs can perform high-efficiency genome editing in the absence of a DSB.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV vectors; genome editing; hematopoietic stem cell; homology-directed repair; targeted nucleases

Mesh:

Substances:

Year:  2019        PMID: 31540849      PMCID: PMC6822228          DOI: 10.1016/j.ymthe.2019.08.019

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  56 in total

1.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  A largely random AAV integration profile after LPLD gene therapy.

Authors:  Christine Kaeppel; Stuart G Beattie; Raffaele Fronza; Richard van Logtenstein; Florence Salmon; Sabine Schmidt; Stephan Wolf; Ali Nowrouzi; Hanno Glimm; Christof von Kalle; Harald Petry; Daniel Gaudet; Manfred Schmidt
Journal:  Nat Med       Date:  2013-06-16       Impact factor: 53.440

3.  Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material.

Authors:  Eduard Ayuso; Véronique Blouin; Martin Lock; Susan McGorray; Xavier Leon; Mauricio R Alvira; Alberto Auricchio; Stephanie Bucher; Abdelwahed Chtarto; K Reed Clark; Christophe Darmon; Monica Doria; Will Fountain; Guangping Gao; Kai Gao; Mauro Giacca; Juergen Kleinschmidt; Barbara Leuchs; Catherine Melas; Hiroaki Mizukami; Marcus Müller; Yvet Noordman; Olivier Bockstael; Keiya Ozawa; Catherine Pythoud; Marina Sumaroka; Richard Surosky; Liliane Tenenbaum; Inge van der Linden; Brigitte Weins; J Fraser Wright; Xinhua Zhang; Lorena Zentilin; Fatima Bosch; Richard O Snyder; Philippe Moullier
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

4.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.

Authors:  Blythe D Sather; Guillermo S Romano Ibarra; Karen Sommer; Gabrielle Curinga; Malika Hale; Iram F Khan; Swati Singh; Yumei Song; Kamila Gwiazda; Jaya Sahni; Jordan Jarjour; Alexander Astrakhan; Thor A Wagner; Andrew M Scharenberg; David J Rawlings
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

5.  Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq.

Authors:  Beeke Wienert; Stacia K Wyman; Christopher D Richardson; Charles D Yeh; Pinar Akcakaya; Michelle J Porritt; Michaela Morlock; Jonathan T Vu; Katelynn R Kazane; Hannah L Watry; Luke M Judge; Bruce R Conklin; Marcello Maresca; Jacob E Corn
Journal:  Science       Date:  2019-04-18       Impact factor: 47.728

6.  In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.

Authors:  Dirk Grimm; Joyce S Lee; Lora Wang; Tushar Desai; Bassel Akache; Theresa A Storm; Mark A Kay
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

7.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Authors:  Jean-Charles Nault; Shalini Datta; Sandrine Imbeaud; Andrea Franconi; Maxime Mallet; Gabrielle Couchy; Eric Letouzé; Camilla Pilati; Benjamin Verret; Jean-Frédéric Blanc; Charles Balabaud; Julien Calderaro; Alexis Laurent; Mélanie Letexier; Paulette Bioulac-Sage; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-08-24       Impact factor: 38.330

8.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.

Authors:  A Barzel; N K Paulk; Y Shi; Y Huang; K Chu; F Zhang; P N Valdmanis; L P Spector; M H Porteus; K M Gaensler; M A Kay
Journal:  Nature       Date:  2014-10-29       Impact factor: 49.962

9.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

10.  Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery.

Authors:  Jianbin Wang; Joshua J DeClercq; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Philip D Gregory; Gary Lee; Michael C Holmes
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

View more
  15 in total

1.  Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors".

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

2.  Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors".

Authors:  Amanda M Dudek; Matthew H Porteus
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

3.  Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors.

Authors:  Saswati Chatterjee
Journal:  Mol Ther       Date:  2019-11-11       Impact factor: 11.454

4.  AAV6 Is Superior to Clade F AAVs in Stimulating Homologous Recombination-Based Genome Editing in Human HSPCs.

Authors:  Amanda M Dudek; Matthew H Porteus
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

5.  Adeno-Associated Virus and Hematopoietic Stem Cells: The Potential of Adeno-Associated Virus Hematopoietic Stem Cells in Genetic Medicines.

Authors:  Saswati Chatterjee; Venkatesh Sivanandam; Kamehameha Kai-Min Wong
Journal:  Hum Gene Ther       Date:  2020-05       Impact factor: 5.695

6.  Knockdown of Astrocytic Monocarboxylate Transporter 4 in the Motor Cortex Leads to Loss of Dendritic Spines and a Deficit in Motor Learning.

Authors:  Adam J Lundquist; George N Llewellyn; Susan H Kishi; Nicolaus A Jakowec; Paula M Cannon; Giselle M Petzinger; Michael W Jakowec
Journal:  Mol Neurobiol       Date:  2021-11-25       Impact factor: 5.590

7.  Rational Selection of CRISPR-Cas9 Guide RNAs for Homology-Directed Genome Editing.

Authors:  Kristina J Tatiossian; Robert D E Clark; Chun Huang; Matthew E Thornton; Brendan H Grubbs; Paula M Cannon
Journal:  Mol Ther       Date:  2020-10-14       Impact factor: 11.454

8.  MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.

Authors:  Lin-Lin Tian; Bin Qian; Xiao-Hui Jiang; Yu-Shan Liu; Tong Chen; Cheng-You Jia; Ya-Li Zhou; Ji-Bin Liu; Yu-Shui Ma; Da Fu; Sen-Tai Ding
Journal:  Int J Genomics       Date:  2021-03-16       Impact factor: 2.326

Review 9.  Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.

Authors:  Byung-Chul Lee; Richard J Lozano; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 11.454

10.  Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.

Authors:  Annalisa Lattanzi; Joab Camarena; Premanjali Lahiri; Helen Segal; Waracharee Srifa; Christopher A Vakulskas; Richard L Frock; Josefin Kenrick; Ciaran Lee; Narae Talbott; Jason Skowronski; M Kyle Cromer; Carsten T Charlesworth; Rasmus O Bak; Sruthi Mantri; Gang Bao; David DiGiusto; John Tisdale; J Fraser Wright; Neehar Bhatia; Maria Grazia Roncarolo; Daniel P Dever; Matthew H Porteus
Journal:  Sci Transl Med       Date:  2021-06-16       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.